Inserm Transfert Initiative

Summary

The leading representative office of defined VC is situated in the Paris. The company was established in Europe in France.

Considering the real fund results, this VC is 14 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2019. The top activity for fund was in 2015. This Inserm Transfert Initiative works on 17 percentage points less the average amount of lead investments comparing to the other organizations.

Besides them, we counted 1 critical employee of this fund in our database.

Among the most successful fund investment fields, there are Biopharma, Health Care. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 3 of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - France. Among the various public portfolio startups of the fund, we may underline ENYO Pharma, ScreenCell, Hemarina

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Inserm Transfert Initiative, startups are often financed by Versant Ventures, OrbiMed, AGORANOV. The meaningful sponsors for the fund in investment in the same round are Bpifrance, Versant Ventures, OrbiMed. In the next rounds fund is usually obtained by Auriga Partners, Versant Ventures, OrbiMed.